Disclosures None.
1742-1241/asset/olbannerleft.gif?v=1&s=b3c9a9b7e70a9c4ca38ddd02fd181116b27464bb)
1742-1241/asset/IJCP_centre.gif?v=1&s=3cfa111b88cbacdad9b3f8950969448b43b466b7)
Endothelial progenitor cells in pulmonary hypertension – dawn of cell-based therapy?
Article first published online: 23 NOV 2009
DOI: 10.1111/j.1742-1241.2009.02232.x
© 2010 The Authors. Journal compilation © 2010 Blackwell Publishing Ltd
Issue
International Journal of Clinical Practice
Special Issue: The Pulmonary Hypertension Reviews: an IJCP Companion Journal
Volume 64, Issue Supplement s165, pages 7–12, January 2010
Additional Information
How to Cite
Toshner, M. and W Morrell, N. (2010), Endothelial progenitor cells in pulmonary hypertension – dawn of cell-based therapy?. International Journal of Clinical Practice, 64: 7–12. doi: 10.1111/j.1742-1241.2009.02232.x
Publication History
- Issue published online: 23 NOV 2009
- Article first published online: 23 NOV 2009
- Paper received 9 September 2009, accepted 21 September 2009
- Abstract
- Article
- References
- Cited By
Summary
There is mounting interest in the concept of endothelial progenitor cell (EPC) therapy for the treatment of pulmonary arterial hypertension (PAH). Recent successful pilot studies in idiopathic PAH have raised questions about the contribution of progenitor cells circulating in the peripheral blood to pulmonary vascular homeostasis and to the process of vascular remodelling. This review will summarise the work performed to date in animal and human therapeutic trials and clarify what is known about the potential contribution of EPCs to the pathophysiology of PAH.